Elevated TRIB3 expression is a promising prognostic marker for ccRCC patients and may play a key role in tumor microenvironments, which indicates a novel molecular mechanism involving TRIB3 in ccRCC and identifies TRIB3 as a novel therapeutic target for ccRCC therapy from bench to clinic. The gene discussed is TRIB3; the disease is neoplasm.